NCT05900258View on ClinicalTrials.gov

Tirbanibulin 1% Ointment for the Treatment of Chronically Sun-damaged Skin on the Face

PHASE4CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

May 11, 2023

Primary Completion Date

November 13, 2023

Study Completion Date

November 13, 2023

Conditions
Actinic Keratosis
Interventions
DRUG

Tirbanibulin

Klisyri® 10 mg/g Ointment (Tirbanibulin) patients receive Tirbanibulin on sun-damaged areas of the face for five days, according to the SmPC.

Trial Locations (1)

Unknown

Medizinische Universität Graz, Graz

All Listed Sponsors
lead

Medical University of Graz

OTHER

NCT05900258 - Tirbanibulin 1% Ointment for the Treatment of Chronically Sun-damaged Skin on the Face | Biotech Hunter | Biotech Hunter